Serveur d'exploration sur le peuplier

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.

Identifieur interne : 003A59 ( Main/Exploration ); précédent : 003A58; suivant : 003A60

The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.

Auteurs : I G Barr [Australie] ; A C Hurt ; N. Deed ; P. Iannello ; C. Tomasov ; N. Komadina

Source :

RBID : pubmed:17350111

Descripteurs français

English descriptors

Abstract

The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used in some countries to control seasonal influenza. While increasing resistance of A(H3) viruses to this class of drug has been reported in recent years, only low levels of resistance were seen with A(H1) viruses until the 2005-2006 influenza season in the USA. In this study we analysed 101 human influenza A viruses isolated in 2006 that were referred to the WHO Collaborating Centre for Reference and Research in Melbourne, from Australia and the surrounding regions, for evidence of resistance to adamantanes. We found that whereas previously A(H1) resistant viruses were rare, 21.8% of the 2006 viruses had a resistant genotype. By comparison, 58.6% of influenza A(H3) viruses isolated in 2006 that were tested at the Centre, had a resistant genotype.

DOI: 10.1016/j.antiviral.2007.01.006
PubMed: 17350111


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.</title>
<author>
<name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name>
<affiliation wicri:level="1">
<nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052, Australia. Ian.Barr@influenzacentre.org</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052</wicri:regionArea>
<placeName>
<settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name>
</author>
<author>
<name sortKey="Deed, N" sort="Deed, N" uniqKey="Deed N" first="N" last="Deed">N. Deed</name>
</author>
<author>
<name sortKey="Iannello, P" sort="Iannello, P" uniqKey="Iannello P" first="P" last="Iannello">P. Iannello</name>
</author>
<author>
<name sortKey="Tomasov, C" sort="Tomasov, C" uniqKey="Tomasov C" first="C" last="Tomasov">C. Tomasov</name>
</author>
<author>
<name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17350111</idno>
<idno type="pmid">17350111</idno>
<idno type="doi">10.1016/j.antiviral.2007.01.006</idno>
<idno type="wicri:Area/Main/Corpus">003C09</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003C09</idno>
<idno type="wicri:Area/Main/Curation">003C09</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003C09</idno>
<idno type="wicri:Area/Main/Exploration">003C09</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.</title>
<author>
<name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name>
<affiliation wicri:level="1">
<nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052, Australia. Ian.Barr@influenzacentre.org</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052</wicri:regionArea>
<placeName>
<settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name>
</author>
<author>
<name sortKey="Deed, N" sort="Deed, N" uniqKey="Deed N" first="N" last="Deed">N. Deed</name>
</author>
<author>
<name sortKey="Iannello, P" sort="Iannello, P" uniqKey="Iannello P" first="P" last="Iannello">P. Iannello</name>
</author>
<author>
<name sortKey="Tomasov, C" sort="Tomasov, C" uniqKey="Tomasov C" first="C" last="Tomasov">C. Tomasov</name>
</author>
<author>
<name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name>
</author>
</analytic>
<series>
<title level="j">Antiviral research</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adamantane (pharmacology)</term>
<term>Adamantane (therapeutic use)</term>
<term>Adolescent (MeSH)</term>
<term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Amino Acid Substitution (MeSH)</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Asia, Southeastern (epidemiology)</term>
<term>Australia (epidemiology)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Drug Resistance, Viral (genetics)</term>
<term>Far East (epidemiology)</term>
<term>Genotype (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Infant (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (drug effects)</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (isolation & purification)</term>
<term>Influenza A Virus, H3N2 Subtype (drug effects)</term>
<term>Influenza A Virus, H3N2 Subtype (genetics)</term>
<term>Influenza A Virus, H3N2 Subtype (isolation & purification)</term>
<term>Influenza, Human (drug therapy)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (virology)</term>
<term>Middle Aged (MeSH)</term>
<term>Pacific Islands (epidemiology)</term>
<term>Prevalence (MeSH)</term>
<term>Rimantadine (pharmacology)</term>
<term>Rimantadine (therapeutic use)</term>
<term>South Africa (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adamantane (pharmacologie)</term>
<term>Adamantane (usage thérapeutique)</term>
<term>Adolescent (MeSH)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Asie du Sud-Est (épidémiologie)</term>
<term>Australie (épidémiologie)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Extrême-Orient (épidémiologie)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Génotype (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Iles du Pacifique (épidémiologie)</term>
<term>Nourrisson (MeSH)</term>
<term>Prévalence (MeSH)</term>
<term>Rimantadine (pharmacologie)</term>
<term>Rimantadine (usage thérapeutique)</term>
<term>République d'Afrique du Sud (épidémiologie)</term>
<term>Résistance virale aux médicaments (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (effets des médicaments et des substances chimiques)</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (isolement et purification)</term>
<term>Sous-type H3N2 du virus de la grippe A (effets des médicaments et des substances chimiques)</term>
<term>Sous-type H3N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A (isolement et purification)</term>
<term>Substitution d'acide aminé (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Adamantane</term>
<term>Antiviral Agents</term>
<term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Adamantane</term>
<term>Antiviral Agents</term>
<term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>Asia, Southeastern</term>
<term>Australia</term>
<term>Far East</term>
<term>Pacific Islands</term>
<term>South Africa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr">
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Drug Resistance, Viral</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>Résistance virale aux médicaments</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en">
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr">
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Adamantane</term>
<term>Antiviraux</term>
<term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Adamantane</term>
<term>Antiviraux</term>
<term>Rimantadine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Asie du Sud-Est</term>
<term>Australie</term>
<term>Extrême-Orient</term>
<term>Grippe humaine</term>
<term>Iles du Pacifique</term>
<term>République d'Afrique du Sud</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Amino Acid Substitution</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Genotype</term>
<term>Humans</term>
<term>Infant</term>
<term>Middle Aged</term>
<term>Prevalence</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Génotype</term>
<term>Humains</term>
<term>Nourrisson</term>
<term>Prévalence</term>
<term>Substitution d'acide aminé</term>
<term>Sujet âgé</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Australie</term>
<term>Afrique du Sud</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used in some countries to control seasonal influenza. While increasing resistance of A(H3) viruses to this class of drug has been reported in recent years, only low levels of resistance were seen with A(H1) viruses until the 2005-2006 influenza season in the USA. In this study we analysed 101 human influenza A viruses isolated in 2006 that were referred to the WHO Collaborating Centre for Reference and Research in Melbourne, from Australia and the surrounding regions, for evidence of resistance to adamantanes. We found that whereas previously A(H1) resistant viruses were rare, 21.8% of the 2006 viruses had a resistant genotype. By comparison, 58.6% of influenza A(H3) viruses isolated in 2006 that were tested at the Centre, had a resistant genotype.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">17350111</PMID>
<DateCompleted>
<Year>2007</Year>
<Month>08</Month>
<Day>06</Day>
</DateCompleted>
<DateRevised>
<Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0166-3542</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>75</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2007</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res</ISOAbbreviation>
</Journal>
<ArticleTitle>The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.</ArticleTitle>
<Pagination>
<MedlinePgn>173-6</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The adamantanes (amantadine and rimantadine) were the first antivirals licensed for use against influenza A viruses and have been used in some countries to control seasonal influenza. While increasing resistance of A(H3) viruses to this class of drug has been reported in recent years, only low levels of resistance were seen with A(H1) viruses until the 2005-2006 influenza season in the USA. In this study we analysed 101 human influenza A viruses isolated in 2006 that were referred to the WHO Collaborating Centre for Reference and Research in Melbourne, from Australia and the surrounding regions, for evidence of resistance to adamantanes. We found that whereas previously A(H1) resistant viruses were rare, 21.8% of the 2006 viruses had a resistant genotype. By comparison, 58.6% of influenza A(H3) viruses isolated in 2006 that were tested at the Centre, had a resistant genotype.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Barr</LastName>
<ForeName>I G</ForeName>
<Initials>IG</Initials>
<AffiliationInfo>
<Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, 45 Poplar Road, Parkville, Melbourne 3052, Australia. Ian.Barr@influenzacentre.org</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hurt</LastName>
<ForeName>A C</ForeName>
<Initials>AC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Deed</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Iannello</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Tomasov</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Komadina</LastName>
<ForeName>N</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2007</Year>
<Month>02</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0T2EF4JQTU</RegistryNumber>
<NameOfSubstance UI="D012299">Rimantadine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>PJY633525U</RegistryNumber>
<NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001210" MajorTopicYN="N" Type="Geographic">Asia, Southeastern</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005202" MajorTopicYN="N" Type="Geographic">Far East</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D010139" MajorTopicYN="N" Type="Geographic">Pacific Islands</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012299" MajorTopicYN="N">Rimantadine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2006</Year>
<Month>11</Month>
<Day>20</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2007</Year>
<Month>01</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2007</Year>
<Month>01</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2007</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2007</Year>
<Month>8</Month>
<Day>7</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2007</Year>
<Month>3</Month>
<Day>14</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">17350111</ArticleId>
<ArticleId IdType="pii">S0166-3542(07)00041-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2007.01.006</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Australie</li>
</country>
<region>
<li>Victoria (État)</li>
</region>
<settlement>
<li>Melbourne</li>
</settlement>
</list>
<tree>
<noCountry>
<name sortKey="Deed, N" sort="Deed, N" uniqKey="Deed N" first="N" last="Deed">N. Deed</name>
<name sortKey="Hurt, A C" sort="Hurt, A C" uniqKey="Hurt A" first="A C" last="Hurt">A C Hurt</name>
<name sortKey="Iannello, P" sort="Iannello, P" uniqKey="Iannello P" first="P" last="Iannello">P. Iannello</name>
<name sortKey="Komadina, N" sort="Komadina, N" uniqKey="Komadina N" first="N" last="Komadina">N. Komadina</name>
<name sortKey="Tomasov, C" sort="Tomasov, C" uniqKey="Tomasov C" first="C" last="Tomasov">C. Tomasov</name>
</noCountry>
<country name="Australie">
<region name="Victoria (État)">
<name sortKey="Barr, I G" sort="Barr, I G" uniqKey="Barr I" first="I G" last="Barr">I G Barr</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A59 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A59 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PoplarV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:17350111
   |texte=   The emergence of adamantane resistance in influenza A(H1) viruses in Australia and regionally in 2006.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:17350111" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PoplarV1 

Wicri

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 12:07:19 2020. Site generation: Wed Nov 18 12:16:31 2020